EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Benjamin J Cowling, George N Okoli

Drugs · 2024

DOI: 10.1007/s40265-024-02083-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Benjamin J Cowling und 1 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong S…. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University Grants Committee, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At various times in recent decades, surges have occurred in optimism about the potential for universal influenza vaccines that provide strong, broad, and long-lasting protection and could substantially reduce the disease burden associated with seasonal influenza epidemics as well as the threat posed by pandemic influenza. Each year more than 500 million doses of seasonal influenza vaccine are administered around the world, with most doses being egg-grown inactivated subunit or split-virion vaccines. These vaccines tend to have moderate effectiveness against medically attended influenza for influenza A(H1N1) and influenza B, and somewhat lower for influenza A(H3N2) where differences between vaccine strains and circulating strains can occur more frequently due to antigenic drift and egg adaptations in the vaccine strains. Several enhanced influenza vaccine platforms have been developed including cell-grown antigen, the inclusion of adjuvants, or higher antigen doses, to improve immunogenicity and protection. During the COVID-19 pandemic there was unprecedented speed in development and roll-out of relatively new vaccine platforms, including mRNA vaccines and viral vector vaccines. These new platforms present opportunities to improve protection for influenza beyond existing products. Other approaches continue to be explored. Incremental improvements in influenza vaccine performance should be achievable in the short to medium term.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanVaccine EfficacyHumansCOVID-19Influenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypePandemicsInfluenza B virus

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. bcowling@hku.hk.
  • Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, Hong Kong, China. bcowling@hku.hk.
  • WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.

Förderung

  • University Grants Committee
  • National Institute of General Medical Sciences

Zitieren

APA

Cowling, B. J., & Okoli, G. N. (2024). Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. Drugs. https://doi.org/10.1007/s40265-024-02083-8

Vancouver

Cowling BJ, Okoli GN. Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. Drugs. 2024. doi:10.1007/s40265-024-02083-8

BibTeX
@article{Cowling2024,
  author = {Cowling, Benjamin J and Okoli, George N},
  title = {Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02083-8}
}
Kostenlos starten →